| Literature DB >> 31915222 |
Lucia Graña-Miraglia1, Benjamin A Evans2, Rafael Franco-Cendejas3, Santiago Castillo-Ramírez4, Luis E López-Jácome3, Melissa Hernández-Durán3, Claudia Adriana Colín-Castro3, Patricia Volkow-Fernández5, Miguel A Cevallos1.
Abstract
Over the last few decades, carbapenemase-producing Acinetobacter baumannii has become a major cause of nosocomial infections all over the world. However, the genome identity of lineages of this species in Latin America has not been studied as much as in developed countries. Here, through a population genomics approach considering the whole genomes of 148 isolates (almost 40 from Mexico and Honduras), we describe the recent emergence of the lineage sequence type 758 (ST758), which belongs to the international clone V and has spread out to Canada, Mexico, Honduras, and Colombia. Notably, this lineage was found to coexist with other A. baumannii lineages in hospitals in Mexico and Honduras. Isolates from this lineage show considerable variation in antibiotic resistance profiles, but most of them are resistant to carbapenems. Moreover, we found a variety of acquired oxacillinase (OXA) families within this lineage and tracked the very recent inception, and subsequent horizontal transmission, of the OXA-239 carbapenemase. This work highlights the urgent need to investigate recently emerged lineages of this species in Latin America and elsewhere, as these might harbor novel antibiotic resistance genes.IMPORTANCE A. baumannii is a major cause of nosocomial infections all over the world. Although many isolates from developed countries have been studied in terms of their genome sequence, isolates from Latin America have been much less studied. In this study, using a population genomics approach considering the whole genomes of 148 isolates, we describe the recent emergence of the lineage ST758 endemic to Latin America and the inception of the OXA-239 carbapenemase. Our study highlights the urgent need to investigate recently emerged lineages of this species in Latin America and elsewhere, as these might harbor novel antibiotic resistance genes.Entities:
Keywords: Acinetobacter baumanniizzm321990; IC5; OXA; OXA β-lactamases; OXA-239; evolutionary biology; genome analysis; infectious diseases; international clones; molecular epidemiology; population genomics
Year: 2020 PMID: 31915222 PMCID: PMC6952199 DOI: 10.1128/mSphere.00801-19
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
FIG 1ML phylogeny showing the relationships among all the isolates. The external circle provides the geographic location of the isolates, when available. Colored dots next to some strains denote the Mexican hospitals. International clones I and II are identified by orange and blue branches, respectively, whereas green branches indicate international clone V. Pink isolates show the ST758 lineage, while the three blue isolates (A023, A029, and H170) clustering within the pink isolates belong to ST1091. The presence of the blaoxa-239 gene is marked with purple triangles. The scale bar gives the number of substitutions per site.
FIG 2Partial eBURST diagrams for Pasteur and Oxford MLST schemes. Only IC5 is shown for both schemes. Rectangles in the Pasteur scheme show the ST found in some Mexican and Honduran strains (ST156) and the most frequent ST found in South America (ST79, in red), whereas the ovals under the Oxford scheme denote the STs found in some Mexican and Honduran strains (ST758 and ST1091).
Antimicrobial susceptibility profiles of the isolates collected from the National Institute of Rehabilitation
| Strain | MIC (mg/liter) (resistance breakpoint) for | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMK (≥64) | GEN (≥16) | CAZ (≥32) | CEP (≥32) | CIP (≥4) | LVX (≥8) | DOR (≥8) | IPM (≥8) | MEM (≥8) | CST (≥4) | TZP (≥128/4) | MIN (≥16) | AMP-sulbactam (≥32/16) | |
| A023 | 8 | 0.125 | 0.25 | ||||||||||
| A158 | 16 | 0.5 | 0.25 | 8/4 | |||||||||
| A580 | 16 | 0.5 | 0.25 | ||||||||||
| A229 | 1 | 0.125 | |||||||||||
| H251 | 0.5 | 0.062 | 1/0.5 | ||||||||||
| H350 | 0.25 | 4 | 16/8 | ||||||||||
| H170 | 8 | 4 | 0.125 | 0.062 | |||||||||
| A465 | 16 | 1 | 0.25 | ||||||||||
| H008 | 16 | 0.125 | 0.5 | ||||||||||
| A278 | 16 | 0.25 | 0.125 | ||||||||||
Underlining indicates intermediate resistance, and bold type denotes resistance. Intermediate and resistant phenotypes were defined as per the CLSI 2018 guidelines. AMK, amikacin; GEN, gentamicin; CAZ, ceftazidime; CEP, cefepime; CIP, ciprofloxacin; LVX, levofloxacin; DOR, doripenem; IPM, imipenem; MEM, meropenem; CST, colistin; TZP, piperacillin-tazobactam; MIN, minocycline; AMP, ampicillin.
FIG 3In silico prediction of antibiotic resistance genes for some strains from ST758 (in black text) and ST1091 (in red text). A heat map shows how many times a gene is present in the strains considered. The different antibiotic resistance classes are color coded. Strains are grouped according to a hierarchical clustering analysis (cladogram on the top).